FDA Acknowledges Efficacy of Rexlemestrocel-L for Chronic Back Pain, Supports BLA Filing
MESO sits 75% above its 52-week low of $9.61.
Summary
Mesoblast received positive feedback from the FDA regarding its rexlemestrocel-L therapy for chronic low back pain, with the agency acknowledging efficacy data and supporting a BLA filing.
Key Events · Product Development and Regulatory · MESO
-
FDA Efficacy Acknowledgment
The FDA acknowledged that the effects on pain intensity for rexlemestrocel-L appear to favor the active arm in the Phase 3 trial (MSB-DR003).
-
Efficacy Support for BLA
The FDA confirmed that a clinically meaningful reduction in pain intensity at 12 months can support product efficacy for a Biologics License Application (BLA).
-
Opioid Reduction Labeling Potential
The FDA stated that robust results on opioid reduction from the trial could be included in the Clinical Studies section of the product labeling, highlighting the therapy's potential to address the opioid crisis.
-
Confirmatory Phase 3 Progress
The second randomized controlled Phase 3 trial (MSB-DR004) is over 50% enrolled and is expected to complete its 300-patient target within three months.
Analysis · MESO · Life Sciences
The FDA's positive feedback on Mesoblast's rexlemestrocel-L for chronic discogenic low back pain significantly de-risks the path to a Biologics License Application (BLA). The agency's acknowledgment that the Phase 3 trial data supports product efficacy and that opioid reduction results could be included in the product labeling are strong indicators of potential approval and commercial success. This development provides clarity and confidence regarding the regulatory strategy for a key pipeline asset.
At the time of this filing, MESO was trading at $16.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $9.61 to $21.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.